Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ATOS Atossa Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: ATOS
Price (delayed)
$1.03
Market cap
$133.05M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$67.82M
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
Highlights
The company's EPS rose by 13% YoY but it fell by 5% QoQ
The net income has grown by 11% YoY but it has contracted by 3.3% from the previous quarter
The quick ratio has declined by 24% year-on-year and by 16% since the previous quarter
The company's equity fell by 24% YoY and by 9% QoQ
Key stats
What are the main financial stats of ATOS
Market
Valuations
Earnings
Shares outstanding
129.17M
Market cap
$133.05M
Enterprise value
$67.82M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.04
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$28.06M
Net income
-$26.34M
EBIT
-$26.34M
EBITDA
-$26.33M
Free cash flow
-$22.31M
Per share
Balance sheet
Liquidity
EPS
-$0.21
EPS diluted
-$0.21
Free cash flow per share
-$0.17
Book value per share
$0.51
Revenue per share
$0
TBVPS
$0.55
Total assets
$70.75M
Total liabilities
$5.43M
Debt
$0
Equity
$65.32M
Working capital
$63.32M
Debt to equity
0
Current ratio
12.67
Quick ratio
12.02
Net debt/EBITDA
2.48
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.7%
Return on equity
-36.3%
Return on invested capital
N/A
Return on capital employed
-40.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATOS stock price
How has the Atossa Therapeutics stock price performed over time
Intraday
15.73%
1 week
26.83%
1 month
62.33%
1 year
-33.12%
YTD
9.1%
QTD
53.07%
Financial performance
How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.06M
Net income
-$26.34M
Gross margin
N/A
Net margin
N/A
The net income has grown by 11% YoY but it has contracted by 3.3% from the previous quarter
The operating income rose by 10% YoY
Price vs fundamentals
How does ATOS's price correlate with its fundamentals
Growth
What is Atossa Therapeutics's growth rate over time
Valuation
What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
2.04
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 13% YoY but it fell by 5% QoQ
The company's equity fell by 24% YoY and by 9% QoQ
ATOS's P/B is 7% above its 5-year quarterly average of 1.9 and 7% above its last 4 quarters average of 1.9
Efficiency
How efficient is Atossa Therapeutics business performance
The return on equity has declined by 16% year-on-year and by 11% since the previous quarter
The ROA has decreased by 13% YoY and by 10% from the previous quarter
Dividends
What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATOS.
Financial health
How did Atossa Therapeutics financials performed over time
The quick ratio has declined by 24% year-on-year and by 16% since the previous quarter
The company's total assets fell by 22% YoY and by 7% QoQ
ATOS's debt is 100% smaller than its equity
The company's equity fell by 24% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.